Drug Profile
Research programme: anti-infectives - PanThera Biopharma
Alternative Names: Anthrax therapies - PanThera Biopharma; Botulinum toxin therapies - PanThera Biopharma; α-Arylamino hydroxamic acids as anthrax lethal factor inhibitors - PanThera BiopharmaLatest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator Hawaii Biotech
- Developer PanThera Biopharma; University of Hawaii
- Class Antitoxins; Small molecules
- Mechanism of Action Anthrax toxin inhibitors; Botulinum toxin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Anthrax; Botulism; Dengue; West Nile virus infections
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for preclinical development in Anthrax in USA (PO, Pill)
- 28 Mar 2022 No recent reports of development identified for preclinical development in Botulism in USA (PO)
- 28 Mar 2022 No recent reports of development identified for preclinical development in Dengue in USA (PO)